Intravitreal Ranibizumab for Diabetic Macular Edema Treatment in Phakic Vitrectomized Eyes
نویسنده
چکیده
Diabetic retinopathy is one of the major complications of diabetes and is a leading cause of vision impairment and blindness. Approximately 75% of persons suffering from type 1 diabetes develop retinopathy, while approximately 50% of persons with type 2 diabetes may develop retinopathy, and approximately 25% of persons with diabetes may develop macular edema [1]. Diabetic macular edema (DME) is the main reason for vision impairment in diabetic patients [2-4]. Vascular endothelial growth factor-A (VEGF-A) has become a frequent target for the treatment of ocular diseases in which angiogenesis plays a role as a result of the growing body of evidence that it is an important regulator of angiogenesis, vascular development Intravitreal Ranibizumab for Diabetic Macular Edema Treatment in Phakic Vitrectomized Eyes
منابع مشابه
Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
PURPOSE To investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients with diabetic macular edema (DME) refractory to ranibizumab or bevacizumab. DESIGN A retrospective chart review. METHODS From September 2013 to March 2016, we identified patients with DME who developed resistance to bevacizumab or ranibizumab. Three monthly intravitreal afliber...
متن کاملShort-term Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized Eyes with Recalcitrant Diabetic Macular Edema and Prior Anti-VEGF Therapy
PURPOSE To determine the efficacy of an intravitreal dexamethasone implant (IDI) for diabetic macular edema (DME) in vitrectomized eyes. METHODS This interventional retrospective consecutive case series included vitrectomized eyes undergoing IDI placement for treatment of recalcitrant DME between June 2011 and June 2014. All patients had previously received anti-VEGF therapy (ranibizumab or b...
متن کاملLong-term effects of ranibizumab on diabetic retinopathy severity and progression.
OBJECTIVE To evaluate effects of intravitreal ranibizumab on diabetic retinopathy (DR) severity over time in 2 phase 3 clinical trials (RIDE, NCT00473382; RISE, NCT00473330) of ranibizumab for diabetic macular edema. METHODS Participants with diabetic macular edema (n=759) were randomized to monthly sham, 0.3-mg ranibizumab, or 0.5-mg ranibizumab intravitreal injections. Macular laser was ava...
متن کاملPrognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
AIMS To investigate the prognostic significance of macular capillary drop-out and previous panretinal laser photocoagulation in diabetic macular oedema treated with intravitreal ranibizumab. METHODS Retrospective observational case series. Treatment-naive patients with diabetic macular oedema that had been treated with intravitreal ranibizumab as per the RESTORE study protocol for at least 12...
متن کاملRanibizumab for Diabetic Macular Edema Refractory to Multiple Prior Treatments.
PURPOSE Diabetic macular edema can be refractory to multiple treatment modalities. Although there have been anecdotal reports of ranibizumab showing efficacy when other modalities provided limited benefit, little has been published on treatment for refractory diabetic macular edema. This study sought to investigate this observation further. METHODS Retrospective chart review. RESULTS Thirty...
متن کامل